The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study.

Author: DellannaFrank, DimkovicNada, LocatelliFrancesco, PontorieroGiuseppe, SpasovskiGoce, WannerChristoph

Paper Details 
Original Abstract of the Article :
BACKGROUND: This study compared the effects of short-term titrated colestilan (a novel non-absorbable, non-calcium, phosphate binder) with placebo, and evaluated the safety and efficacy of colestilan over 1 year compared with sevelamer, in patients with chronic kidney disease (CKD) 5D. METHODS: Thi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005560/

データ提供:米国国立医学図書館(NLM)

Comparing Colestilan, Placebo, and Sevelamer for Hyperphosphatemia in Chronic Kidney Disease

Hyperphosphatemia, an elevated level of phosphorus in the blood, is a common complication of chronic kidney disease (CKD). This research compares the effectiveness of colestilan, a novel phosphate binder, with placebo and sevelamer, a commonly used phosphate binder, in patients with CKD 5D. The study, conducted over a year, evaluated the efficacy and safety of these treatments in controlling phosphorus levels and managing associated cardiovascular risk factors. The findings suggest that colestilan is an effective and well-tolerated alternative to sevelamer in managing hyperphosphatemia in this patient population.

Effective and Safe Treatment Options for Hyperphosphatemia

This study reveals that colestilan is an effective and safe treatment option for hyperphosphatemia in CKD 5D patients. The findings indicate that colestilan produces significant reductions in serum phosphorus levels, similar to sevelamer, while demonstrating favorable safety and tolerability profiles. This research provides valuable information for healthcare providers seeking to manage hyperphosphatemia in CKD 5D patients.

Managing Phosphorus Levels in Chronic Kidney Disease

Hyperphosphatemia is a significant challenge in CKD patients, often contributing to cardiovascular disease and other complications. This study underscores the importance of effective phosphate binder therapy in managing this condition. The findings suggest that colestilan is a valuable addition to the therapeutic arsenal for CKD 5D patients, offering a promising alternative to sevelamer.

Dr.Camel's Conclusion

This study provides valuable insights into the treatment of hyperphosphatemia in CKD 5D patients. The findings suggest that colestilan is an effective and well-tolerated alternative to sevelamer, offering a promising treatment option for this patient population. As a camel traversing a vast desert, we must continually seek out new and innovative solutions to address the challenges of chronic kidney disease and improve the health and well-being of patients.

Date :
  1. Date Completed 2014-09-26
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24302608

DOI: Digital Object Identifier

PMC4005560

Related Literature

Article Analysis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.